# A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

> **NCT05810948** · PHASE2 · COMPLETED · sponsor: **argenx** · enrollment: 73 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** efgartigimod IV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05810948
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-21
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-09-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810948, "A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05810948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*